Rusul Al-Marayaty

Rusul Al-Marayaty

Auto-generated profile, based on publicly available information

Rusul Al-Marayaty

MedStar Washington Hospital Center 10 , Washington, District of Columbia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically “hot” tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TILs from “cold” tumors with a low tumor mutational burden, such as many sarcoma types, poses a challenge due to limited infiltration of the tumor microenvironment (TME) with lymphocytes, low frequencies of tumor antigen–specific, high-affinity T cells, and incompletely understood mechanisms of immune-resistance prevailing in the TME. Here, we report the successful generation and expansion of TILs engineered with regulatable, membrane-bound IL15 (cytoTIL15 cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2. Comprehensive spatial profiling of the TME revealed ubiquitous collagen and myeloid infiltration as major resistance mechanisms, whereas lymphocytic infiltration was largely restricted to peripheral regions of the tumors, a relevant consideration when sampling these tumors for TIL harvest. Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

17 June 2026 in Cancer Discovery
Verified
Journal Article
Closed access
BSBrett A. Schroeder
Brett A. Schroeder
CMChirayu Mohindroo
Chirayu Mohindroo
AMAnna-Lena Meinhardt
Anna-Lena Meinhardt
NTNobuyuki Takahashi
Nobuyuki Takahashi
YZYang Zhang
Yang Zhang
ATAnish Thomas
Anish Thomas
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.

2 June 2026
Verified
Other
Open access
PDF file
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Table S1: IHC antibody clones and dilution factors

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Table S2: Flow cytometry antibodies clones and dulution factors

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S7: Representative IHC images of Chondrosarcoma tumors.

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S1: Gating strategy for pre-REP phenotyping.